Healthcare
FDA Recognizes Value of Tobacco Harm Reduction
Regulators approve less-harmful alternative to tobacco.
Key Healthcare Policy Priorities for the 119th Congress
The new Congress should promote patient centered care, increase accessibility, affordability, and transparency.
Medicare Must Be Reformed and Saved Not Expanded
Expanding benefits for medicare will hasten the program’s impending depletion.
340B Drug Discount Program is a Nightmare
Like many other well-intended programs 340B has ended up both wasting money and failing to provide benefits for patients.
Price Controls Are Always a Bad Idea
Prices controls have always disrupted the marketplace and created shortages or excesses.
The Case for 340B Reform Is Made on Capitol Hill
At a Capitol Hill briefing on the urgent need for reforms to the 340B Drug Pricing Program, the case was made for prompt action to fix the program. The event took place at the Senate Visitors Center on September 23, 2024, and was hosted by the...
USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The IRA Has Undermined Medicare Part D
The Inflation Reduction Act creates instability in the Medicare Part D Program.
Not-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
CAGW Submits Comments on FTC's Interim Staff Report on PBMs
Overregulating PBMs will drive up prescription drug costs and be a disservice to the millions of patients that benefit from them.
New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee's recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
